A Pioneer in Personalized Healthcare
Phenogen Sciences provides physicians and patients with novel, predictive testing and risk assessment tools for patient-specific health management in the areas of oncology and women’s health. Phenogen’s innovative products provide greater insight into a patient’s personal genetic makeup, expanding the base of medical information for each patient so that physicians can make more-informed decisions regarding surveillance and treatment options.
Phenogen Sciences, Inc., a US division of Australia-based Genetic Technologies Limited, was established in 2010 as a global expansion strategy of the company’s oncology and cancer management diagnostics business. As a pioneer in personalized healthcare, Phenogen Sciences offers novel predictive testing and risk assessment tools that help physicians proactively manage the health of their patients. Phenogen’s lead product line, GeneType, are a series of clinically validated predictive risk tests that combine genomic and clinical data to categorize a patient’s personal risk of developing disease.
Its parent company, Genetic Technologies Limited (NASDAQ: GENE) is based in Melbourne, Australia. For more than 20 years, the company has provided laboratory services in molecular diagnostics and was an early pioneer in recognizing important new applications for ‘non-coding’ DNA (Deoxyribonucleic Acid). The company has since been granted patents in 24 countries around the world.